What is Utah Med Prods's earnings per share (EPS)?

Utah Med Prods (UTMD) reported diluted earnings per share of $3.48 for fiscal year 2025. This represents a -12.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Utah Med Prods Financials

UTMD

Source SEC Filings (10-K/10-Q) Updated Mar 27, 2026 Currency USD FYE March

This page shows Utah Med Prods (UTMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 74/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Utah Med Prods has an operating margin of 29.6%, meaning the company retains $30 of operating profit per $100 of revenue. This strong profitability earns a score of 88/100, reflecting efficient cost management and pricing power. This is down from 33.2% the prior year.

Growth

Utah Med Prods's revenue declined 5.8% year-over-year, from $40.9M to $38.5M. This contraction results in a growth score of 24/100.

Leverage

100

Utah Med Prods carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 37.62, Utah Med Prods holds $37.62 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

100

Utah Med Prods converts 37.2% of revenue into free cash flow ($14.3M). This strong cash generation earns a score of 100/100.

Returns

Utah Med Prods's ROE of 9.5% shows moderate profitability relative to equity, earning a score of 32/100. This is down from 11.8% the prior year.

Altman Z-Score Safe

39.87

Utah Med Prods scores 39.87, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($201.0M) relative to total liabilities ($3.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

5/9

Utah Med Prods passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

1.30x

For every $1 of reported earnings, Utah Med Prods generates $1.30 in operating cash flow ($14.7M OCF vs $11.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$38.5M

YoY-5.8%

5Y CAGR-1.8%

10Y CAGR-0.4%

Utah Med Prods generated $38.5M in revenue in fiscal year 2025. This represents a decrease of 5.8% from the prior year.

EBITDA

$14.4M

YoY-12.4%

5Y CAGR-7.2%

10Y CAGR-1.2%

Utah Med Prods's EBITDA was $14.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 12.4% from the prior year.

Net Income

$11.3M

YoY-18.7%

5Y CAGR+0.9%

10Y CAGR-0.5%

Utah Med Prods reported $11.3M in net income in fiscal year 2025. This represents a decrease of 18.7% from the prior year.

EPS (Diluted)

$3.48

YoY-12.1%

5Y CAGR+3.4%

Utah Med Prods earned $3.48 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 12.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$14.3M

YoY-1.9%

5Y CAGR-5.8%

10Y CAGR+0.5%

Utah Med Prods generated $14.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 1.9% from the prior year.

Cash & Debt

$85.8M

YoY+3.4%

5Y CAGR+10.7%

10Y CAGR+13.9%

Utah Med Prods held $85.8M in cash against $225K in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY-4.5%

5Y CAGR-2.7%

Utah Med Prods had 3M shares outstanding in fiscal year 2025. This represents a decrease of 4.5% from the prior year.

Margins & Returns

Gross Margin

57.1%

YoY-1.9pp

5Y CAGR-3.4pp

10Y CAGR-3.1pp

Utah Med Prods's gross margin was 57.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.9 percentage points from the prior year.

Operating Margin

29.6%

YoY-3.6pp

5Y CAGR-2.9pp

10Y CAGR-9.4pp

Utah Med Prods's operating margin was 29.6% in fiscal year 2025, reflecting core business profitability. This is down 3.6 percentage points from the prior year.

Net Margin

29.3%

YoY-4.6pp

5Y CAGR+3.7pp

10Y CAGR-0.2pp

Utah Med Prods's net profit margin was 29.3% in fiscal year 2025, showing the share of revenue converted to profit. This is down 4.6 percentage points from the prior year.

Return on Equity

9.5%

YoY-2.3pp

5Y CAGR-1.0pp

10Y CAGR-7.5pp

Utah Med Prods's ROE was 9.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 2.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$668K

YoY-17.8%

5Y CAGR+6.6%

10Y CAGR+2.5%

Utah Med Prods invested $668K in research and development in fiscal year 2025. This represents a decrease of 17.8% from the prior year.

Share Buybacks

$8.4M

YoY-58.2%

5Y CAGR+3.7%

Utah Med Prods spent $8.4M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 58.2% from the prior year.

Capital Expenditures

$371K

YoY+61.3%

5Y CAGR-15.5%

10Y CAGR+7.7%

Utah Med Prods invested $371K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 61.3% from the prior year.

UTMD Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$38.5M-5.8%	$40.9M-18.6%	$50.2M-3.9%	$52.3M+6.6%	$49.1M+16.3%	$42.2M
Cost of Revenue	$16.5M-1.4%	$16.8M-17.0%	$20.2M+0.5%	$20.1M+10.7%	$18.1M+9.1%	$16.6M
Gross Profit	$22.0M-8.9%	$24.1M-19.6%	$30.0M-6.7%	$32.2M+4.1%	$30.9M+21.0%	$25.5M
R&D Expenses	$668K-17.8%	$813K+45.2%	$560K+13.6%	$493K-6.3%	$526K+8.2%	$486K
SG&A Expenses	$7.9M+0.6%	$7.8M-28.9%	$11.0M+5.9%	$10.4M+3.1%	$10.1M+3.0%	$9.8M
Operating Income	$11.4M-16.1%	$13.6M-19.0%	$16.8M-15.2%	$19.8M+4.8%	$18.9M+37.7%	$13.7M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$2.8M-3.6%	$2.9M-15.2%	$3.5M-17.5%	$4.2M-2.0%	$4.3M+40.5%	$3.0M
Net Income	$11.3M-18.7%	$13.9M-16.6%	$16.6M+1.0%	$16.5M+11.4%	$14.8M+37.0%	$10.8M
EPS (Diluted)	$3.48-12.1%	$3.96-13.3%	$4.57+1.1%	$4.52+11.9%	$4.04+37.4%	$2.94

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$9.8M-1.4%	$10.0M+2.5%	$9.7M+6.0%	$9.2M-8.5%	$10.0M-3.8%	$10.4M-8.3%	$11.3M-8.1%	$12.3M
Cost of Revenue	$4.2M-3.4%	$4.4M+4.5%	$4.2M	N/A	$4.2M+1.4%	$4.1M-9.3%	$4.6M	N/A
Gross Profit	$5.6M+0.2%	$5.6M+1.0%	$5.5M+4.0%	$5.3M-8.3%	$5.8M-7.2%	$6.3M-7.6%	$6.8M-4.7%	$7.1M
R&D Expenses	$167K+23.7%	$135K-12.3%	$154K	N/A	$172K-32.5%	$255K-4.1%	$266K	N/A
SG&A Expenses	$2.8M+24.8%	$2.3M+1.5%	$2.2M	N/A	$2.3M-10.7%	$2.6M-2.2%	$2.6M	N/A
Operating Income	$2.6M-18.3%	$3.2M+1.4%	$3.2M	N/A	$3.3M-2.8%	$3.4M-11.5%	$3.9M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$678K-14.0%	$788K-3.5%	$817K	N/A	$616K-18.7%	$758K-10.0%	$842K	N/A
Net Income	$2.6M-13.7%	$3.0M+0.2%	$3.0M+4.8%	$2.9M-18.6%	$3.6M+3.2%	$3.5M-12.7%	$4.0M-7.7%	$4.3M
EPS (Diluted)	$0.82-12.8%	$0.94+2.2%	$0.92+7.0%	$0.86-15.7%	$1.02+4.1%	$0.98-10.1%	$1.09-7.6%	$1.18

UTMD Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$122.5M0.0%	$122.5M-9.5%	$135.5M+9.4%	$123.9M+7.1%	$115.6M+3.5%	$111.7M
Current Assets	$97.7M+1.5%	$96.3M-9.4%	$106.3M+18.2%	$89.9M+22.9%	$73.2M+17.5%	$62.3M
Cash & Equivalents	$85.8M+3.4%	$83.0M-10.7%	$92.9M+23.7%	$75.1M+23.1%	$61.0M+18.2%	$51.6M
Inventory	$7.9M-10.0%	$8.8M-8.0%	$9.6M+8.7%	$8.8M+33.6%	$6.6M+6.0%	$6.2M
Accounts Receivable	$3.5M-14.0%	$4.1M+20.7%	$3.4M-38.8%	$5.5M+7.9%	$5.1M+25.0%	$4.1M
Goodwill	$14.1M+3.5%	$13.6M-0.8%	$13.7M+2.5%	$13.4M-5.3%	$14.1M-0.5%	$14.2M
Total Liabilities	$3.3M-35.9%	$5.1M-28.5%	$7.1M-25.7%	$9.6M+13.2%	$8.5M-4.8%	$8.9M
Current Liabilities	$2.6M-30.8%	$3.8M-20.2%	$4.7M-21.0%	$6.0M+59.1%	$3.7M-1.2%	$3.8M
Long-Term Debt	$225K	$0	$0	$0	$0	$0
Total Equity	$119.3M+1.6%	$117.4M-8.5%	$128.3M+12.3%	$114.3M+6.6%	$107.1M+4.2%	$102.8M
Retained Earnings	$128.7M-0.5%	$129.3M-6.5%	$138.3M+9.8%	$126.0M+9.3%	$115.3M+3.9%	$111.0M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$122.0M+1.0%	$120.8M-1.4%	$122.5M0.0%	$122.5M-5.5%	$129.7M-0.3%	$130.0M-4.0%	$135.4M0.0%	$135.5M
Current Assets	$96.5M+2.3%	$94.4M-2.1%	$96.4M+0.1%	$96.3M-5.2%	$101.7M-0.7%	$102.3M-4.5%	$107.1M+0.8%	$106.3M
Cash & Equivalents	$84.3M+2.5%	$82.2M-1.4%	$83.3M+0.4%	$83.0M-6.2%	$88.5M-0.9%	$89.2M-4.9%	$93.8M+1.0%	$92.9M
Inventory	$8.1M-1.4%	$8.2M-4.8%	$8.6M-1.9%	$8.8M-3.2%	$9.1M+0.5%	$9.1M-2.0%	$9.2M-3.6%	$9.6M
Accounts Receivable	$3.7M+2.6%	$3.6M-7.9%	$3.9M-3.7%	$4.1M+10.1%	$3.7M+1.4%	$3.7M+2.1%	$3.6M+5.9%	$3.4M
Goodwill	$14.1M-1.0%	$14.2M+3.1%	$13.8M+1.4%	$13.6M-3.2%	$14.0M+2.8%	$13.6M0.0%	$13.6M-0.4%	$13.7M
Total Liabilities	$3.7M+13.9%	$3.3M-40.3%	$5.5M+7.1%	$5.1M-7.0%	$5.5M-8.1%	$6.0M-22.3%	$7.7M+7.8%	$7.1M
Current Liabilities	$3.0M+33.6%	$2.3M-47.9%	$4.3M+15.1%	$3.8M+9.4%	$3.4M-12.8%	$3.9M-28.0%	$5.5M+16.2%	$4.7M
Long-Term Debt	N/A	N/A	$269K	$0	N/A	N/A	N/A	$0
Total Equity	$118.3M+0.6%	$117.5M+0.4%	$117.0M-0.3%	$117.4M-5.5%	$124.2M+0.1%	$124.1M-2.9%	$127.7M-0.4%	$128.3M
Retained Earnings	$128.0M+0.9%	$126.9M-1.0%	$128.2M-0.8%	$129.3M-3.5%	$134.1M-1.0%	$135.3M-2.6%	$139.0M+0.5%	$138.3M

UTMD Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$14.7M-0.9%	$14.8M-33.4%	$22.3M+5.4%	$21.1M-0.3%	$21.2M+5.3%	$20.1M
Capital Expenditures	$371K+61.3%	$230K-64.0%	$639K-21.0%	$809K+46.6%	$552K-35.8%	$860K
Free Cash Flow	$14.3M-1.9%	$14.6M-32.5%	$21.6M+6.4%	$20.3M-1.5%	$20.7M+7.1%	$19.3M
Investing Cash Flow	-$371K-78.4%	-$208K+67.4%	-$639K+21.9%	-$818K-48.2%	-$552K+35.8%	-$860K
Financing Cash Flow	-$12.3M+48.2%	-$23.8M-472.3%	-$4.2M+24.1%	-$5.5M+49.7%	-$10.9M-1.6%	-$10.7M
Dividends Paid	$4.0M-6.5%	$4.3M-0.5%	$4.3M+35.4%	$3.2M-72.4%	$11.5M+178.5%	$4.1M
Share Buybacks	$8.4M-58.2%	$20.0M	$0-100.0%	$2.5M	$0-100.0%	$7.0M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$3.9M+35.0%	$2.9M-35.6%	$4.5M+52.0%	$2.9M-23.8%	$3.9M+39.6%	$2.8M-47.6%	$5.3M-1.1%	$5.3M
Capital Expenditures	$27K-47.1%	$51K-72.3%	$184K+1944.4%	$9K-89.9%	$89K-19.1%	$110K+400.0%	$22K-75.6%	$90K
Free Cash Flow	$3.9M+36.5%	$2.8M-34.1%	$4.3M+46.2%	$2.9M-22.3%	$3.8M+42.0%	$2.7M-49.5%	$5.3M+0.2%	$5.2M
Investing Cash Flow	-$27K+47.1%	-$51K+72.3%	-$184K-1944.4%	-$9K+89.9%	-$89K+22.6%	-$115K-2400.0%	$5K+105.6%	-$90K
Financing Cash Flow	-$1.6M+63.4%	-$4.5M-5.9%	-$4.2M+45.3%	-$7.7M-57.5%	-$4.9M+31.6%	-$7.2M-80.5%	-$4.0M-271.9%	-$1.1M
Dividends Paid	$988K-1.3%	$1.0M-1.6%	$1.0M-2.0%	$1.0M-1.3%	$1.1M-2.7%	$1.1M-0.7%	$1.1M+1.7%	$1.1M
Share Buybacks	$653K-81.3%	$3.5M+8.3%	$3.2M-52.0%	$6.7M+73.5%	$3.9M-39.6%	$6.4M+114.1%	$3.0M	$0

UTMD Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	57.1%-1.9pp	59.0%-0.8pp	59.8%-1.8pp	61.6%-1.4pp	63.0%+2.5pp	60.6%
Operating Margin	29.6%-3.6pp	33.2%-0.2pp	33.4%-4.4pp	37.9%-0.6pp	38.5%+6.0pp	32.5%
Net Margin	29.3%-4.6pp	33.9%+0.8pp	33.1%+1.6pp	31.5%+1.4pp	30.1%+4.5pp	25.6%
Return on Equity	9.5%-2.3pp	11.8%-1.1pp	13.0%-1.5pp	14.4%+0.6pp	13.8%+3.3pp	10.5%
Return on Assets	9.2%-2.1pp	11.3%-1.0pp	12.3%-1.0pp	13.3%+0.5pp	12.8%+3.1pp	9.7%
Current Ratio	37.62+12.0	25.64+3.1	22.56+7.5	15.09-4.4	19.53+3.1	16.42
Debt-to-Equity	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.00
FCF Margin	37.2%+1.5pp	35.7%-7.4pp	43.1%+4.2pp	38.9%-3.2pp	42.1%-3.6pp	45.7%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	57.1%+0.9pp	56.2%-0.8pp	57.0%-1.1pp	58.1%+0.1pp	58.0%-2.1pp	60.1%+0.5pp	59.7%+2.1pp	57.6%
Operating Margin	26.6%-5.5pp	32.1%-0.4pp	32.5%	N/A	33.4%+0.4pp	33.1%-1.2pp	34.2%	N/A
Net Margin	26.8%-3.8pp	30.6%-0.7pp	31.3%-0.4pp	31.7%-3.9pp	35.6%+2.4pp	33.2%-1.7pp	34.9%+0.1pp	34.8%
Return on Equity	2.2%-0.4pp	2.6%0.0pp	2.6%+0.1pp	2.5%-0.4pp	2.9%+0.1pp	2.8%-0.3pp	3.1%-0.2pp	3.3%
Return on Assets	2.2%-0.4pp	2.5%+0.0pp	2.5%+0.1pp	2.4%-0.4pp	2.8%+0.1pp	2.7%-0.3pp	2.9%-0.2pp	3.2%
Current Ratio	32.06-9.8	41.87+19.6	22.29-3.3	25.64-4.0	29.59+3.6	25.98+6.4	19.57-3.0	22.56
Debt-to-Equity	0.030.0	0.03+0.0	0.000.0	0.00-0.0	0.040.0	0.05-0.0	0.06+0.1	0.00
FCF Margin	39.3%+10.9pp	28.3%-15.7pp	44.1%+12.1pp	32.0%-5.7pp	37.6%+12.2pp	25.5%-20.8pp	46.3%+3.8pp	42.5%

Similar Companies

$187.8M

$200.3M

$212.9M

$58.4M

$155.4M

Frequently Asked Questions

What is Utah Med Prods's annual revenue?

Utah Med Prods (UTMD) reported $38.5M in total revenue for fiscal year 2025. This represents a -5.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Utah Med Prods's revenue growing?

Utah Med Prods (UTMD) revenue declined by 5.8% year-over-year, from $40.9M to $38.5M in fiscal year 2025.

Is Utah Med Prods profitable?

Yes, Utah Med Prods (UTMD) reported a net income of $11.3M in fiscal year 2025, with a net profit margin of 29.3%.

What is Utah Med Prods's EBITDA?

Utah Med Prods (UTMD) had EBITDA of $14.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Utah Med Prods have?

As of fiscal year 2025, Utah Med Prods (UTMD) had $85.8M in cash and equivalents against $225K in long-term debt.

What is Utah Med Prods's gross margin?

Utah Med Prods (UTMD) had a gross margin of 57.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Utah Med Prods's operating margin?

Utah Med Prods (UTMD) had an operating margin of 29.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Utah Med Prods's net profit margin?

Utah Med Prods (UTMD) had a net profit margin of 29.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Utah Med Prods's return on equity (ROE)?

Utah Med Prods (UTMD) has a return on equity of 9.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Utah Med Prods's free cash flow?

Utah Med Prods (UTMD) generated $14.3M in free cash flow during fiscal year 2025. This represents a -1.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Utah Med Prods's operating cash flow?

Utah Med Prods (UTMD) generated $14.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Utah Med Prods's total assets?

Utah Med Prods (UTMD) had $122.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Utah Med Prods's capital expenditures?

Utah Med Prods (UTMD) invested $371K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Utah Med Prods spend on research and development?

Utah Med Prods (UTMD) invested $668K in research and development during fiscal year 2025.

Does Utah Med Prods buy back shares?

Yes, Utah Med Prods (UTMD) spent $8.4M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Utah Med Prods have outstanding?

Utah Med Prods (UTMD) had 3M shares outstanding as of fiscal year 2025.

What is Utah Med Prods's current ratio?

Utah Med Prods (UTMD) had a current ratio of 37.62 as of fiscal year 2025, which is generally considered healthy.

What is Utah Med Prods's debt-to-equity ratio?

Utah Med Prods (UTMD) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Utah Med Prods's return on assets (ROA)?

Utah Med Prods (UTMD) had a return on assets of 9.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Utah Med Prods's Altman Z-Score?

Utah Med Prods (UTMD) has an Altman Z-Score of 39.87, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Utah Med Prods's Piotroski F-Score?

Utah Med Prods (UTMD) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Utah Med Prods's earnings high quality?

Utah Med Prods (UTMD) has an earnings quality ratio of 1.30x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Utah Med Prods?

Utah Med Prods (UTMD) scores 74 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.